Cargando…

R5 Clade C SHIV Strains with Tier 1 or 2 Neutralization Sensitivity: Tools to Dissect Env Evolution and to Develop AIDS Vaccines in Primate Models

BACKGROUND: HIV-1 clade C (HIV-C) predominates worldwide, and anti-HIV-C vaccines are urgently needed. Neutralizing antibody (nAb) responses are considered important but have proved difficult to elicit. Although some current immunogens elicit antibodies that neutralize highly neutralization-sensitiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siddappa, Nagadenahalli B., Watkins, Jennifer D., Wassermann, Klemens J., Song, Ruijiang, Wang, Wendy, Kramer, Victor G., Lakhashe, Samir, Santosuosso, Michael, Poznansky, Mark C., Novembre, Francis J., Villinger, François, Else, James G., Montefiori, David C., Rasmussen, Robert A., Ruprecht, Ruth M.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908149/ https://www.ncbi.nlm.nih.gov/pubmed/20657739 http://dx.doi.org/10.1371/journal.pone.0011689

Ejemplares similares

Vaccination against Heterologous R5 Clade C SHIV: Prevention of Infection and Correlates of Protection
por: Lakhashe, Samir K., et al.
Publicado: (2011)

SHIV-1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys
por: Humbert, Michael, et al.
Publicado: (2008)

Passive immunization with polyclonal anti-SHIV IgG: partial protection or increased acquisition of heterologous tier 2 SHIV – depending on IgG dose
por: Sholukh, AM, et al.
Publicado: (2012)

An Anti-HIV-1 V3 Loop Antibody Fully Protects Cross-Clade and Elicits T-Cell Immunity in Macaques Mucosally Challenged with an R5 Clade C SHIV
por: Watkins, Jennifer D., et al.
Publicado: (2011)

Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose
por: Sholukh, Anton M, et al.
Publicado: (2014)

Schistosoma mansoni Enhances Host Susceptibility to Mucosal but Not Intravenous Challenge by R5 Clade C SHIV
por: Siddappa, Nagadenahalli B., et al.
Publicado: (2011)

R5-SHIV Induces Multiple Defects in T Cell Function during Early Infection of Rhesus Macaques Including Accumulation of T Reg Cells in Lymph Nodes
por: Santosuosso, Michael, et al.
Publicado: (2011)

Cooperation Between Systemic IgG1 and Mucosal Dimeric IgA2 Monoclonal Anti-HIV Env Antibodies: Passive Immunization Protects Indian Rhesus Macaques Against Mucosal SHIV Challenges
por: Gong, Siqi, et al.
Publicado: (2021)

Modified Adenovirus Prime-Protein Boost Clade C HIV Vaccine Strategy Results in Reduced Viral DNA in Blood and Tissues Following Tier 2 SHIV Challenge
por: Malherbe, Delphine C., et al.
Publicado: (2021)

Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges
por: Lakhashe, Samir K., et al.
Publicado: (2022)

Acute Schistosoma mansoni Infection Increases Susceptibility to Systemic SHIV Clade C Infection in Rhesus Macaques after Mucosal Virus Exposure
por: Chenine, Agnès-Laurence, et al.
Publicado: (2008)

Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers
por: Pauthner, Matthias G., et al.
Publicado: (2019)

Limited SHIV env diversification in macaques failing oral antiretroviral pre-exposure prophylaxis
por: Zheng, Qi, et al.
Publicado: (2012)

Variations in the Biological Functions of HIV-1 Clade C Envelope in a SHIV-Infected Rhesus Macaque during Disease Progression
por: Tso, For Yue, et al.
Publicado: (2013)

Analysis of transcribed human endogenous retrovirus W env loci clarifies the origin of multiple sclerosis-associated retrovirus env sequences
por: Laufer, Georg, et al.
Publicado: (2009)

Specific Substitutions in Region V2 of gp120 env confer SHIV Neutralisation Resistance
por: Pisil, Yalcin, et al.
Publicado: (2020)

Dynamics of Envelope Evolution in Clade C SHIV-Infected Pig-Tailed Macaques during Disease Progression Analyzed by Ultra-Deep Pyrosequencing
por: Tso, For Yue, et al.
Publicado: (2012)

Construction of SHIVs expressing quaternary neutralization epitopes in Env and mimicking the neutralization phenotype of typical HIV-1 isolates
por: Theis, JF, et al.
Publicado: (2012)

Advances in SIV/SHIV Non-Human Primate Models of NeuroAIDS
por: Moretti, Sonia, et al.
Publicado: (2021)

Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles
por: Brouwer, Philip J. M., et al.
Publicado: (2021)

Maternal HIV-1 Env Vaccination for Systemic and Breast Milk Immunity To Prevent Oral SHIV Acquisition in Infant Macaques
por: Eudailey, Joshua A., et al.
Publicado: (2018)

Differential Pathogenicity of SHIV KB9 and 89.6 Env Correlates with Bystander Apoptosis Induction in CD4+ T cells
por: Mehmetoglu-Gurbuz, Tugba, et al.
Publicado: (2019)

Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env Sequences
por: Tartaglia, Lawrence J., et al.
Publicado: (2016)

Pre-existing neutralizing antibody mitigates B cell dysregulation and enhances the Env-specific antibody response in SHIV-infected rhesus macaques
por: Jaworski, Juan Pablo, et al.
Publicado: (2017)

An Efficiently Cleaved HIV-1 Clade C Env Selectively Binds to Neutralizing Antibodies
por: Boliar, Saikat, et al.
Publicado: (2015)

Neutralization tiers of HIV-1
por: Montefiori, David C., et al.
Publicado: (2018)

Development of a HIV-1 vaccine using an orally-administered, replication-competent adenovirus serotype 4 vector expressing Env clade C glycoprotein
por: Alexander, J, et al.
Publicado: (2012)

Evaluation of chimeric antigen receptor T cell therapy in non-human primates infected with SHIV or SIV
por: Iwamoto, Nami, et al.
Publicado: (2021)

Identification of a clade A HIV envelope immunogen from Protocol G that elicits neutralizing antibodies to tier 2 viruses
por: Hoffenberg, S, et al.
Publicado: (2012)

Priming with DNA encoding functional trimers and boosting with soluble trimeric protein elicited tier 2 neutralizing antibodies in non-human primates
por: Chakrabarti, BK, et al.
Publicado: (2012)

Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques
por: Negri, Donatella, et al.
Publicado: (2016)

Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques
por: Dobard, Charles W, et al.
Publicado: (2015)

IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells
por: Blasi, Maria, et al.
Publicado: (2018)

Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates
por: van Schooten, Jelle, et al.
Publicado: (2021)

Live-virus exposure of vaccine-protected macaques alters the anti-HIV-1 antibody repertoire in the absence of viremia
por: Bachler, Barbara C, et al.
Publicado: (2013)

Envés
por: Amara, Luigi, 1971-
Publicado: (2003)

Vaccine-Induced, High-Magnitude HIV Env-Specific Antibodies with Fc-Mediated Effector Functions Are Insufficient to Protect Infant Rhesus Macaques against Oral SHIV Infection
por: Curtis, Alan D., et al.
Publicado: (2022)

Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines
por: Weaver, Eric A., et al.
Publicado: (2009)

Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines
por: Weiss, Svenja, et al.
Publicado: (2022)

Inducing Cross-Clade Neutralizing Antibodies against HIV-1 by Immunofocusing
por: Humbert, Michael, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_g4i69mgnp5bj47fl443uup3nc5